Search results for

The revised Patent Act, which has significantly amended Korea's compulsory licensing system, will come into force on December 1 2005. The Presidential Decree, which regulates the details of the revised Act has been made public and will also take effect on the same date.

As IP owners enter into more and more cross-border licensing deals, they must be increasingly vigilant to the legal traps that await the unwary. Rodney De Boos and Jeff Bergmann of Davies Collison Cave explain how to negotiate Australia's legal landscape

Australia has a range of remedies available for IP owners who want to stop the trafficking of products that infringe their trade marks and copyright at the border. Melissa Preston and Thai Loi of Shelston IP provide a guide to the rules

Emma Barraclough, Hong Kong

Several journalism incidents over the summer have left a big question mark as to where the line is drawn in relation to freedom of the press in the UAE. Early in June, a female reporter for a prominent daily English newspaper was on her way to Greece when she was stopped at the airport and informed that there was a warrant for her arrest. The warrant was prompted by an article she had written in February about a man who was reportedly slashing women in the nearby Emirate of Sharjah. The police said a victim had raised a complaint against the reporter but it soon became clear that the arrest was made by the Sharjah police who later contended that her article may have helped the attacker escape by alerting him to their investigation.

According to the last paragraph of article 78 of the Industrial Property Law (LPI), when resolving a patent invalidity claim, the Mexican Institute of Industrial Property (IMPI) can, besides denying invalidity, declare the whole patent invalid or partial invalidity.

Of all the IP regimes in Australia, copyright has seen the most dynamic developments and reforms in the last 18 months, particularly in relation to digital technology. Cameron Harvey and David Wilson of Deacons explain what the changes mean for IP owners and users

In May 2003, when India's Patent Act was amended, a new Section 107A was introduced. This provided for a research exemption as an exception to the general rules of patent infringement. Commonly known as a Bolar provision, this research exemption enables a manufacturer of generic drugs to use a patented invention to obtain marketing approval without the patent owner's permission before the patent expires. The generic drug maker can then market their own version of the patented drug as soon as the patent expires.

Consumer groups argue that parallel trading leads to cheaper prices but trade mark owners say it jeopardizes their long-term relationships with both distributors and consumers. Peter Hallett of Griffith Hack explains what IP owners can do to stop the trade in Australia

Stéphanie Bodoni, London